You are viewing the site in preview mode

Skip to main content

Table 6 Logistic regression analysis of predictors for clinical improvement in OMG and GMG patients

From: The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study

Clinical phenotype

Variables

Univariate analysis

Multivariate analysis

  

OR (95% CI)

P value

OR (95% CI)

P value

OMG (n = 107)

Baseline MG-ADL

1.843 (1.335, 2.543)

 < 0.001*

2.318 (1.486, 3.616)

 < 0.001*

Age at the onset

0.963 (0.944, 0.983)

 < 0.001*

0.948 (0.920, 0.977)

 < 0.001*

Onset in March

12.800 (1.208, 135.579)

0.034*

7.282 (0.524, 101.183)

0.139

Vaccination

0.198 (0.042, 0.942)

0.042*

0.399 (0.049, 3.240)

0.399

GMG (n = 87)

Affect Limb muscles

0.351 (0.131, 0.942)

0.038*

0.705 (0.232, 2.143)

0.537

Prednisolone

3.867 (1.055, 14.178)

0.041*

2.012 (0.478, 8.462)

0.340

Baseline MG-ADL

1.495 (1.154, 1.935)

0.002*

1.374 (1.040, 1.814)

0.025*

  1. Note: *P-value < 0.05 is significant. n = 107 (60 for OMG patients with clinical improvement, 47 for OMG patients without clinical improvement). n = 87 (63 for GMG patients with clinical improvement, 24 for GMG patients without clinical improvement)
  2. Abbreviations: MG myasthenia gravis, OMG Ocular MG, GMG Generalized MG, MG-ADL MG activities of daily living profile